Many Americans are hesitant to be vaccinated against Covid-19, according to research from Invisibly.
Oxford scientists are preparing to rapidly produce new versions of their vaccine to combat emerging more contagious Covid-19 variants discovered in the UK, South Africa and Brazil, The Telegraph reported.
A panel of outside advisers to the U.S. Food and Drug Administration overwhelmingly endorsed emergency use of Moderna Inc.’s coronavirus vaccine, virtually assuring a second option for protecting against Covid-19 for a pandemic-ravaged nation.
Anthony S. Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), noted that it would take time – possibly months – before people 18 years of age and younger could get a Covid-19 vaccine because clinical trials were either underway or had not yet begun.
An AstraZeneca executive said he felt encouraged by “incredibly promising” large-scale Covid-19 vaccine trial results unveiled by New York-based Pfizer and the company’s German partner BioNTech.
Moderna Inc. Chief Executive Officer Stéphane Bancel expects interim results from the company’s Covid-19 vaccine trial in November and that the U.S government could give an emergency use nod in December, the Wall Street Journal reported.
Moderna Inc. will not be ready to apply for emergency authorization for the potential Covid-19 vaccine mRNA-1273 before the U.S. presidential election in November, the Financial Times reported, citing the company’s chief executive officer.
The U.S. Food and Drug Administration is expected to issue a new and more stringent guidance regarding a potential Emergency Use Authorization (EUA) for a Covid–19 vaccine.
Britain will host clinical trials where volunteers are deliberately infected with the new coronavirus to test the effectiveness of vaccine candidates, the Financial Times reported, citing people involved in the project.
Although it’s increasingly likely that one of the Covid-19 vaccines being tested will be approved or receive Emergency Use Authorization (EUA) before the end of 2020, experts are increasingly warning that widespread distribution may take a much longer time.